ReviewInternational journal of molecular sciences2014
Emerging biomarkers in heart failure and cardiac cachexia.
Review in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study.ESC heart failure · 2018Trial
- Latest Updates on Sarcopenia and Cachexia: Insights from the 17th Sarcopenia, Cachexia, and Wasting Disorders Conference.Journal of bone metabolism · 2025Article
- Electroacupuncture and vagus nerve stimulation are emerging therapies for hyperemesis gravidarum management.Frontiers in neurology · 2025Review
- CT-Diagnosed Sarcopenia and Cardiovascular Biomarkers in Patients Undergoing Transcatheter Aortic Valve Replacement: Is It Possible to Predict Muscle Loss Based on Laboratory Tests?-A Multicentric Retrospective Analysis.Journal of personalized medicine · 2022Article
- Nutrition Assessment and Dietary Interventions in Heart Failure: JACC Review Topic of the Week.Journal of the American College of Cardiology · 2022Review
- Effects of exercise on serum ischemia-modified albumin, brain natriuretic peptide and copeptin levels in boxers and kick boxers.The Pan African medical journal · 2022Article
- The Biomarkers for Acute Myocardial Infarction and Heart Failure.BioMed research international · 2020Review
- Analysis of GDF15 and IGFBP7 in Hyperemesis Gravidarum Support Causality.Geburtshilfe und Frauenheilkunde · 2019Article
- Cardiac expression of neutrophil gelatinase-associated lipocalin in a model of cancer cachexia-induced cardiomyopathy.ESC heart failure · 2019Article
- Cardiac Obesity and Cardiac Cachexia: Is There a Pathophysiological Link?Journal of obesity · 2019Review
- Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.Archives of medical science : AMS · 2018Article
- Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum.Nature communications · 2018Article
- Selecting Potential Pharmacological Interventions in Sarcopenia.Drugs & aging · 2017Review
- Heart failure management in the elderly - a public health challenge.Wiener klinische Wochenschrift · 2016Review
- ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker.Journal of cachexia, sarcopenia and muscle · 2016Article
- Cardiac cachexia: hic et nunc.Journal of cachexia, sarcopenia and muscle · 2016Review
- Beyond the Limits: Clinical Utility of Novel Cardiac Biomarkers.BioMed research international · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarkers are objective tools with an important role for diagnosis, prognosis and therapy optimization in patients with heart failure (HF). To date, natriuretic peptides are closest to optimal biomarker standards for clinical implications in HF. Therefore, the efforts to identify and test new biomarkers in HF are reasonable and justified. Along the natural history of HF, cardiac cachexia may develop, and once at this stage, patient performance and prognosis is particularly poor. For these reasons, numerous biomarkers reflecting hormonal, inflammatory and oxidative stress pathways have been investigated, but only a few convey relevant information. The complex pathophysiology of HF appears far too complex to be embraced by a single biomarker; thus, a combined approach appears reasonable. With these considerations, we have reviewed the recent developments in the field to highlight key candidates with diagnostic, prognostic and therapy optimization properties, either alone or in combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.